The economic impact of multiple sclerosis to the patients and their families in Norway.

BACKGROUND: Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs. OBJECTIVE: We aimed to estimate the magnitude of these economic costs in Norway. METHOD: We collected data through a postal questionnaire survey targeting 922 MS patients in Hordaland County, western Norway, in 2013-2014; 546 agreed to participate and were included. The questionnaire included clinical and demographic characteristics, volume and cost of MS-related resource use, work participation, income, government financial support, and disability status. RESULTS: The mean annual total economic costs for the patients and their families were €11,603. Indirect costs accounted for 66% and were lower for women than for men. The direct costs were nearly identical for men and women. The costs increased up to Expanded Disability Status Scale score 6 except for steps between 3 and 4 where it remained nearly constant. The costs reduced from EDSS 6 to 8, and increased from 8 to 9. Lifetime costs ranged from €24,897 to €70,021 for patients with late disease onset and slow progression, and between €441,934 and €574,860 for patients with early onset and rapid progression. CONCLUSION: The economic costs of MS impose a heavy burden on the patients and their families. Supplementing the information on the cost of MS to society, our finding should be included as background information in decisions on reimbursing and allocating public resources for the well-being of MS patients and their families.

Fatigue in multiple sclerosis: associations with health-related quality of life and physical performance.

BACKGROUND AND PURPOSE: fatigue is a common, but still one of the least understood symptoms in multiple sclerosis (MS). We aimed to investigate whether fatigue was associated with demographic-, clinical-, health-related quality of life (HRQoL)- and physical performance variables, and whether change in fatigue after treatment was associated with changes in HRQoL and physical performance. METHODS: sixty patients were included for inpatient physiotherapy. Fifty-six patients completed the study and were available for analysis. Fatigue (Fatigue Severity Scale; FSS), HRQoL (Multiple Sclerosis Impact Scale; MSIS-29) and physical performance (walking ability and balance) were assessed at screening, baseline, after treatment and at follow-up after 3 and 6 months. We analysed possible associations between fatigue and other variables at baseline by regression models, and between change in fatigue versus changes in both HRQoL and physical performance variables after physiotherapy by correlation analysis. RESULTS: fatigue at baseline was associated with HRQoL (explained 21.9% of variance), but not with the physical performance tests. Change in fatigue was correlated with change in HRQoL, but not with changes in physical performance. All measures were improved after treatment (P ≤ 0.001). While improvements in fatigue and HRQoL were lost at follow-up, improvements in physical performance tests were maintained for at least 6 months (P ≤ 0.05). CONCLUSIONS: fatigue was associated with HRQoL at baseline. Improvement in fatigue seemed to be related to other factors than improvement in physical performance. A broader strategy including both physical and psychological dimensions seems to be needed to improve fatigue over the long-term.

The influence of warm versus cold climate on the effect of physiotherapy in multiple sclerosis.

OBJECTIVE: To compare the effect of inpatient physiotherapy in a warm versus cold climate in short- and long-term perspectives. METHODS: Sixty multiple sclerosis (MS) patients with gait problems, without heat intolerance, were included in a randomized cross-over study of 4-week inpatient physiotherapy in warm (Spain) and cold (Norway) climate. The primary outcome, 6-min walk test (6MWT), and secondary physical performance and self-reported measures were scored at screening, baseline, after treatment and at 3 and 6 months of follow-up. Treatment effects were analysed by mixed models. RESULTS: After treatment, the mean walking distance had increased by 70 m in Spain and 49 m in Norway (P = 0.060). Improvement in favour of warm climate was demonstrated at 6 months of follow-up, 43 m (Spain) compared to 20 m (Norway) (P = 0.048). The patients reported less exertion after walking (6MWT) in favour of treatment in Spain at all time points (P < 0.05). No significant differences in change were detected for the other physical performance measures. Most self-reported measures showed more improvement after treatment in Spain, but these improvements were not sustained at follow-up. CONCLUSION: The results indicate that MS patients without heat intolerance have additional benefits from physiotherapy in a warm climate.

Psychometric properties of a Norwegian version of Multiple Sclerosis Impact Scale (MSIS-29).

OBJECTIVES: To examine psychometric properties of Multiple Sclerosis Impact Scale (MSIS-29) for use in Norwegian patients with multiple sclerosis. METHODS: Translation was performed according to international guidelines. The questionnaire was answered by 64 patients prior to and at a screening session, and re-answered by 59 patients before and after 4 weeks of physiotherapy. RESULTS: Internal consistency (α) was 0.92 for the physical and 0.85 for the psychological subscales. Reliability by intraclass correlation coefficients were 0.86 for the physical and 0.81 for the psychological subscales, smallest detectable change being 18.4 and 21.1, respectively. The physical but not the psychological subscale demonstrated mostly satisfactory associations with other physical measures. Responsiveness by area under the receiver operating characteristics curve was 0.83 and 0.76, respectively. As hypothesized, effect size was larger for the physical (1.01) than for the psychological (0.76) subscale after treatment. CONCLUSIONS: MSIS-29, Norwegian Version demonstrated satisfactory psychometric properties.

[Botulinum toxin A--effect on spasticity]. / Botulinumtoksin A--effekt på spastisitet.

BACKGROUND: Severe spasticity may lead to problems of movement and function, pain and hygiene, and may be difficult to treat. A team of neurologists and physiotherapists evaluated the effect of botulinum toxin A (BTX-A) on spasticity. MATERIAL AND METHODS: Ten patients with central nervous disorders were included in this study. Function, pain and personal hygiene were assessed before and after injections with BTX-A. RESULTS: Nine patients experienced improvement of function and/or pain relief. One patient had improved perception in his hand, and one patient needed only two injections to stop a vicious circle. The effect varied from patient to patient. It seemed that patients with some preserved motor control in the spastic limb could use it to learn more appropriate movement strategies. INTERPRETATION: We recommend that doctors and physiotherapists work together to identify muscle groups that need to be targeted for injection and evaluate consequences of the treatment. Injections with BTX-A should be combined with physiotherapy.